The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers

European Respiratory Journal

Volumn 41, Issue 1, 2013, Pages 239-241

  Kirsten, Anne ^a   Watz, Henrik ^a   Pedersen, Frauke ^a   Holz, Olaf ^a,b   Smith, Rachel ^c   Bruin, Gerard ^d   Koehne Voss, Stephan ^d   Magnussen, Helgo ^a   Waltz, David A ^c  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SECUKINUMAB;

ADULT; AIRWAY NEUTROPHILIA; AREA UNDER THE CURVE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; LABORATORY TEST; LETTER; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHIL COUNT; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; SPIROMETRY; SPUTUM ANALYSIS; VITAL SIGN;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-17; LEUKOCYTE DISORDERS; LUNG DISEASES; MALE; NEUTROPHILS; OZONE; TIME FACTORS; TREATMENT FAILURE;

EID: 84872203681     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00123612     Document Type: Letter

References (10)

1. Lindén A, Laan M, Anderson GP. Neutrophils, interleukin-17A and lung disease. Eur Respir J 2005; 25: 159-172.
2. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2: 52ra72.
3. Holz O, Tal-Singer R, Kanniess F, et al. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol 2005; 45: 498-503.
4. Holz O, Khalilieh S, Ludwig-Sengpiel A, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010; 35: 564-570.
5. Kirsten A, Watz H, Kretschmar G, et al. Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects - a double blind, randomized, placebo-controlled, cross-over clinical trial. Pulm Pharmacol Ther 2011; 24: 555-558.
6. Pichavant M, Goya S, Meyer EH, et al. Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17. J Exp Med 2008; 205: 385-393.
7. Ferretti S, Bonneau O, Dubois GR, et al. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003; 170: 2106-2112.
8. Glader P, Smith ME, Malmhall C, et al. Interleukin-17-producing T-helper cells and related cytokines in human airways exposed to endotoxin. Eur Respir J 2010; 36: 1155-1164.
9. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976; 84: 304-315.
10. Nguyen LT, Lim S, Oates T, et al. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005; 99: 200-207.